View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 5, 2021

EmitBio’s technology shows evidence to inactivate multiple coronaviruses

EmitBio has announced that new evidence from laboratory testing showed that its light technology can inactivate several coronaviruses, including the one that causes Covid-19 and Middle East respiratory syndrome coronavirus (MERS-CoV).

EmitBio has announced that new evidence from laboratory testing showed that its light technology can inactivate several coronaviruses, including the one that causes Covid-19 and Middle East respiratory syndrome coronavirus (MERS-CoV).

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The evidence hints at the potential of effectiveness of the company’s technology against SARS-CoV-2 variants.

EmitBio executive chairman Neal Hunter said: “Over the last 20 years, we have seen three life-threatening coronavirus outbreaks, SARS-CoV-1, MERS-CoV, and now, SARS-CoV-2 – the virus that causes Covid-19.

“Having this countermeasure at-the-ready will not only help current Covid-19 patients but will also provide protection against future outbreaks.

“On a scale of genetic variation from A to Z, if you consider SARS-CoV-2 as A, and MERS-CoV as Z, and we can kill them both, then we can most likely kill everything in between.”

According to the World Health Organization (WHO), MERS-CoV has a 35%-40% fatality rate in people who test positive. Most cases are linked to the Arabian Peninsula residents even though cases were reported outside of this region because of travellers returning home from Saudi Arabia.

The company noted that precise wavelengths of light achieved over 99.9% reduction in MERS-CoV viral load at energy doses proven safe to human tissue in a controlled laboratory environment.

Furthermore, the data indicate the potential of visible light therapy in killing coronaviruses that may exist in animal populations but do not yet exist in humans.

EmitBio Virology Research director Dr Adam Cockrell said: “What we learned from these findings is that our visible light is effective at inactivating viral particles before infecting the cell, much like antibodies inactivate viruses and prevent them from entering cells.”

EmitBio has also developed a novel, hand-held treatment device for at-home use for treating mild-to-moderate Covid-19 in adults who test positive for SARS-CoV-2.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network